临床肿瘤学杂志

参考文献

[1]关律昕,甘子沁,黄广涛,等.中国中老年人黑色素瘤疾病负担及十年趋势预测[J].浙江大学学报(医学版),2025,54(1):1-9.

[2]Yu L,Yan F,Qi J,et al.Burden of melanoma in China and its provinces from 1990 to 2021:an analysis for the global burden of disease study 2021[J].Front Public Health,2024,12:1486617.

[3]Sutthatarn P,Davidoff AM,Bahrami A,et al.Regional lymph node evaluation in pediatric conventional melanoma subtype:a single-center 10-year review[J].Pediatr Surg Int,2024,40(1):68.

[4]Holmberg CJ,Mikiver R,Isaksson K,et al.Prognostic significance of sentinel lymph node status in thick primary melanomas(>4 mm)[J].Ann Surg Oncol,2023,30(13):8026-8033.

[5]刘巍峰,斯璐,牛晓辉.CSCO黑色素瘤诊疗指南解读——前哨淋巴结活检的意义、操作及治疗专家共识[J].临床肿瘤学杂志,2021,26(9):827-837.

[6]Me E.The role of clinical prediction tools to risk stratify patients with melanoma after a positive sentinel lymph node biopsy[J].Ann Surg Oncol,2021,28(8):4082-4083.

[7]Vuoristo M,Muhonen T,Koljonen V, et al.Long-term prognostic value of sentinel lymph node tumor burden in survival of melanoma patients[J].Acta Oncol,2021,60(6):803-807.

[8]Rajaee A,Sadr-Eshkevari P,McMasters KM,et al.Predictors of nonsentinel lymph node metastasis in cutaneous melanoma:a systematic review and meta-analysis[J].J Surg Res,2021,260:506-515.

[9]Broman KK,Hughes T,Dossett L,et al.Active surveillance of patients who have sentinel node positive melanoma:an international,multi-institution evaluation of adoption and early outcomes after the multicenter selective lymphadenectomy trialⅡ(MSLT-2)[J].Cancer,2021,127(13):2251-2261.

[10]Broman KK,Hughes TM,Dossett LA,et al.Surveillance of sentinel node-positive melanoma patients with reasons for exclusion from MSLT-Ⅱ:multi-institutional propensity score matched analysis[J].J Am Coll Surg,2021,232(4):424-431.

[11]Curti BD,Faries MB.Recent advances in the treatment of melanoma[J].N Engl J Med,2021,384(23):2229-2240.

[12]Mouna O,Hans sens C,Meyers M,et al.Is there still a place for lymph node dissection for stageⅢmelanoma since the approval of adjuvant therapy[J].Curr Opin Oncol,2025,37(2):110-115.

[13]Roccuzzo G,Macagno N,Grignani P,et al.Treatment patterns and outcomes of stageⅢmelanoma patients with positive sentinel lymph node biopsy:a real-life experience[J].J Clin Med,2024,13(17):5238.

[14]Cowman AW,Lourdault K,Hanes D,et al.Surgical management of thick primary cutaneous melanoma in the US[J].Cancer Med,2025,14(4):e70578.

[15]McCahill LE.Changes in the surgical management of melanoma and measures to implement change[J].Am J Surg,2025,241:116129.

[16]Shen C,Shah JK,Cevallos P,et al.Lymphadenectomy after melanoma-a national analysis of recurrence rates and risk of lymphedema[J].Ann Plast Surg,2024,92(4S Suppl 2):S284-S292.

[17]Jiminez V,Montgomery KB,Hollenquest B,et al.Long-term outcomes of nodal surveillance practices in sentinel node positive melanoma:an early post MSLT-Ⅱcohort[J].Am J Surg,2025,239:116049.

[18]Baecher H,Gerken M,Knoedler L,et al.Complete lymph node dissection in cutaneous melanoma patients with positive sentinel lymphnode:outcome and predictors in a retrospective cohort study over 16years[J].J Plast Reconstr Aesthet Surg,2024,92:33-47.

[19]Martinez Campayo N,Paradela de la Morena S,Pértega-Diaz S,et al.Prognostic significance of sentinel lymph node biopsy in elderly with cutaneous melanoma:systematic review and meta-analysis[J].Int J Dermatol,2024,63(7):873-880.

[20]Scoville SD,Stanek JR,Rinehardt H,et al.Comparison of outcomes between surveillance ultrasound and completion lymph node dissection in children and adolescents with sentinel lymph node-positive cutaneous melanoma[J].Ann Surg,2024,279(3):536-541.

[21]Kukushkina M,Korovin S,Solodiannikova O,et al.Long-term outcomes of sentinel lymph node biopsy versus lymph node observation in melanoma patients[J].Probl Radiac Med Radiobiol,2023,28:513-518.

[22]Palve J,Ylitalo L,Luukkaala T,et al.Sentinel node tumor burden in prediction of prognosis in melanoma patients[J].Clin Exp Metastasis,2020,37(2):365-376.

[23]Yalcin CE,Melenkis S,Demir L,et al.Investigation of prognostic factors for non-sentinel lymph node metastasis in patients undergoing sentinel lymph node biopsy for cutaneous malignant melanoma:experience from a reference centre in Turkey[J].J Plast Reconstr Aesthet Surg,2024,91:167-172.

[24]Rutkowski P,Szydlowski K,Nowecki ZI,et al.The long-term results and prognostic significance of cutaneous melanoma surgery using sentinel node biopsy with triple technique[J].World J Surg Oncol,2015,13:299.

[25]Balaban A,McCollum KJ,Al-Rohil RN.StageⅢmelanoma:a proposed staging model that outperforms the american joint committee on cancer eighth edition staging system[J].Am J Surg Pathol,2024,48(10):1318-1325.

[26]Reinhart JP,Campbell EH,Proffer SL,et al.Incidence and mortality trends of primary cutaneous melanoma:a 50-year rochester epidemiologic project study[J].JAAD Int,2024,16:144-154.

[27]Tropea S,Del Fiore P,Maurichi A,et al.The role of sentinel node tumor burden in modeling the prognosis of melanoma patients with positive sentinel node biopsy:an Italian melanoma intergroup study(N=2,086)[J].BMC Cancer,2022,22(1):610.

[28]Sun W,Xu Y,Yang J,et al.The prognostic significance of non-sentinel lymph node metastasis in cutaneous and acral melanoma patients-a multicenter retrospective study[J].Cancer Commun(Lond),2020,40(11):586-597.

[29]Borgognoni L,Bellucci F,Urso C,et al.Enhancing the prognostic role of melanoma sentinel lymph nodes through microscopic tumour burden characterization:clinical usefulness in patients who do not undergo complete lymph node dissection[J].Melanoma Res,2019,29(2):163-171.

[30]Madu MF,Wouters MWJM,van Akkooi ACJ.Sentinel node biopsy in melanoma:current controversies addressed[J].Eur J Surg Oncol,2017,43(3):517-533.

[31]Starz H,Siedlecki K,Balda BR.Sentinel lymphonodectomy and s-classification:a successful strategy for better prediction and improvement of outcome of melanoma[J].Ann Surg Oncol,2004,11(3Suppl):162S-8S.

[32]van der Ploeg APT,van Akkooi ACJ,Haydu LE,et al.The progno stic significance of sentinel node tumour burden in melanoma patients:an international,multicenter study of 1539 sentinel node-positive melanoma patients[J].Eur J Cancer,2014,50(1):111-120.

[33]van Akkooi ACJ,Verhoef C,Eggermont AMM.Importance of tumor load in the sentinel node in melanoma:clinical dilemmas[J].Nat Rev Clin Oncol,2010,7(8):446-454.

[34]Nagaraja V, Eslick GD.Is complete lymph node dissection after a positive sentinel lymph node biopsy for cutaneous melanoma always necessary?A meta-analysis[J].Eur J Surg Oncol,2013,39(7):669-680.

[35]Egger ME,Bower MR,Czyszczon IA,et al.Comparison of sentinel lymph node micrometastatic tumor burden measurements in melanoma[J].J Am Coll Surg,2014,218(4):519-528.

[36]Han D,van Akkooi ACJ,Straker RJ,et al.Current management of melanoma patients with nodal metastases[J].Clin Exp Metastasis,2022,39(1):181-199.

[37]Dewar DJ,Newell B,Green MA,et al.The microanatomic location of metastatic melanoma in sentinel lymph nodes predicts nonsentinel lymph node involvement[J].J Clin Oncol,2004,22(16):3345-3349.

[38]Loidi-Pascual L,Librero J,Córdoba-Iturriagagoitia A,et al.Sentinel node tumor burden in cutaneous melanoma.Survival with competing risk analysis and influence in relapses and non-sentinel node status:retrospective cohort study with long follow-up in a spanish population[J].Arch Dermatol Res,2022,314(4):369-378.

[39]Kretschmer L,Mitteldorf C,Hellriegel S,et al.The sentinel node invasion level(SNIL)as a prognostic parameter in melanoma[J]. Mod Pathol,2021,34(10):1839-1849.

[40]Lo M,Robinson A,Wade R,et al.Extracapsular spread in melanoma lymphadenopathy:prognostic implications,classification,and management[J].Ann Surg Oncol,2021,28(3):1642-1653.

[41]Hussain Z,Heaton MJ,Snelling AP,et al.Risk stratification of sentinel node metastasis disease burden and phenotype in stageⅢmelanoma patients[J].Ann Surg Oncol,2023,30(3):1808-1819.

[42]Verver D,van Klaveren D,van Akkooi ACJ,et al.Risk stratification of sentinel node-positive melanoma patients defines surgical management and adjuvant therapy treatment considerations[J].Eur J Cancer,2018,96:25-33.

[43]Pearlman NW,McCarter MD,Frank M,et al.Size of sentinel node metastases predicts other nodal disease and survival in malignant melanoma[J].Am J Surg,2006,192(6):878-881.

[44]van Akkooi ACJ,de Wilt JHW,Verhoef C,et al.Clinical relevance of melanoma micrometastases(<0.1 mm)in sentinel nodes:are these nodes to be considered negative?[J].Ann Oncol,2006,17(10):1578-1585.

[45]Cochran AJ,Wen DR,Huang RR,et al.Sentinel lymph node melanoma metastases:assessment of tumor burden for clinical prediction of outcome in the first Multicenter Selective Lymphadenectomy Trial(MSLT-I)[J].Eur J Surg Oncol,2022,48(6):1280-1287.

[46]Mitra D,Ologun G,Keung EZ,et al.Nodal recurrence is a primary driver of early relapse for patients with sentinel lymph node-positive melanoma in the modern therapeutic era[J].Ann Surg Oncol,2021,28(7):3480-3489.

[47]van der Ploeg APT,van Akkooi ACJ,Rutkowski P,et al.Prognosis in patients with sentinel node-positive melanoma is accurately defined by the combined Rotterdam tumor load and Dewar topography criteria[J].J Clin Oncol,2011,29(16):2206-2214.

[48]Leiter U,Stadler R,Mauch C,et al.Final analysis of DeCOG-SLT trial:no survival benefit for complete lymph node dissection in patients with melanoma with positive sentinel node[J].J Clin Oncol,2019,37(32):3000-3008.

[49]Leiter U,Stadler R,Mauch C,et al.Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma(DeCOG-SLT):a multicentre,randomised,phase 3trial[J].Lancet Oncol,2016,17(6):757-767.

[50]中国临床肿瘤学会黑色素瘤专家委员会.CSCO黑色素瘤诊疗指南(2024版)[M].北京:人民卫生出版社,2024.

[51]Cadili A,Scolyer RA,Brown PT,et al.Total sentinel lymph node tumor size predicts nonsentinel node metastasis and survival in patients with melanoma[J].Ann Surg Oncol,2010,17(11):3015-3020.

[52]Lin X,Sun W,Ren M,et al.Prediction of nonsentinel lymph node metastasis in acral melanoma with positive sentinel lymph nodes[J].J Surg Oncol,2023,128(8):1407-1415.

[5 3]Gershenwald JE,Andtbacka RH,Prieto VG,et al.Microscopic tumor burden in sentinel lymph nodes predicts synchronous nonsentinel lymph node involvement in patients with melanoma[J].J Clin Oncol,2008,26(26):4296-4303.

[54]Murali R,Desilva C,Thompson JF,et al.Non-sentinel node risk score(N-SNORE):a scoring system for accurately stratifying risk of non-sentinel node positivity in patients with cutaneous melanoma with positive sentinel lymph nodes[J].J Clin Oncol,2010,28(29):4441-4449.

[55]Bhutiani N,Egger ME,Stromberg AJ,et al.A model for predicting low probability of nonsentinel lymph node positivity in melanoma patients with a single positive sentinel lymph node[J].J Surg Oncol,2018,118(6):922-927.

[56]Bertolli E,Franke V,Calsavara VF,et al.Validation of a nomogram for non-sentinel node positivity in melanoma patients,and its clinical implications:a brazilian-dutch study[J].Ann Surg Oncol,2019,26(2):395-405.

[57]Rossi CR,Mocellin S,Campana LG,et al.Prediction of non-sentinel node status in patients with melanoma and positive sentinel node biopsy:an italian melanoma intergroup(IMI)study[J].Ann Surg Oncol,2018,25(1):271-279.